Cosmo Pharmaceuticals N : Half-Year Results 2022 Webcast Presentation
July 28, 2022 at 01:08 am EDT
Share
DELIVERING
INNOVATION +
IMPROVING LIVES
HALF-YEAR RESULTS 2022
JULY 28, 2022
Safe harbour
This presentation may include forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management.
The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that any of its plans will be achieved. Actual results may differ materially from those set forth in this presentation due to the risks and uncertainties inherent in Cosmo's ability to develop and expand its business, successfully complete development of its current product candidates and current and future collaborations for the development and commercialization of its product candidates and reduce costs (including staff costs). Any statements regarding the development of the
market for drugs to treat IBD diseases, Cosmo's anticipated
future revenues, capital expenditures, financial resources and other similar statements, may be "forward-looking" and as such involve risks and uncertainties and risks related to the collaboration between Cosmo and its current or future partner and/or any business activities that are integrated into
Cosmo's business and risks following any potential for delays in the development programs for its products. No assurance can be given that the results anticipated in such forward-looking statements will occur. Actual events or
results may differ materially from Cosmo's expectations due to factors which include, but are not limited to, a lack of information regarding any future partners or acquisitions, increased competition, Cosmo's ability to finance expansion plans, the results of Cosmo's research and development activities, the success of Cosmo's products and
partnerships, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Cosmo assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.
You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Cosmo undertakes no obligation to revise or update this presentation.
Cosmo Pharmaceuticals | Half Year Results 2022
2
01 Introduction
Alessandro Della Chà - CEO
02 H1 2022 Key Events & Products Update Alessandro Della Chà - CEO
03 2022 Financial Review Niall Donnelly - CFO
04 2022 Key Priorities & Guidance Alessandro Della Chà - CEO
Cosmo Pharmaceuticals | Half Year Results 2022
3
INTRODUCTION
ALESSANDRO DELLA CHÀ CEO
Cosmo Pharmaceuticals | Half Year Results 2022
4
Who we are
Cosmo is a pharmaceutical company which develops and manufactures innovative products in the fields of:
Gastroenterology
HealthTech
Dermatology
Gastrointestinal (GI) diseases
Artificial Intelligence applications
Skin and Hair loss
in endoscopy
Inflammatory Bowel Disease (IBD)
Colorectal cancer (CRC)
Colon - lesion detection
Acne
Irritable Bowel Syndrome - Diarrhoea
Colon - further applications
Androgenetic Alopecia
(IBS-D)
underway
Infectious diseases
Cosmo Pharmaceuticals | Half Year Results 2022
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Cosmo Pharmaceuticals NV published this content on 28 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2022 05:07:04 UTC.
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellersâ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.